📣 VC round data is live. Check it out!
- Public Comps
- 111
111 Valuation Multiples
Discover revenue and EBITDA valuation multiples for 111 and similar public comparables like SOFTMAX, Mister Spex, Beforepay, Deepnoid and more.
111 Overview
About 111
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People’s Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
Founded
2013
HQ

Employees
1.2K
Website
Sectors
Financials (FY)
EV
$6M
Valuation Multiples
Start free trial111 Financials
111 reported last fiscal year revenue of $2B and EBITDA of $4M.
In the same fiscal year, 111 generated $106M in gross profit, $4M in EBITDA, and had net loss of ($10M).
111 P&L
In the most recent fiscal year, 111 reported revenue of $2B and EBITDA of $4M.
111 is unprofitable as of last fiscal year, with gross margin of 6%, EBITDA margin of 0%, and net margin of (1%).
Financial data powered by Morningstar, Inc.
111 Stock Performance
111 has current market cap of $53M, and enterprise value of $6M.
111's stock price is $6.05.
111 has an EPS (earnings per share) of $-1.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $53M | 0.0% | — | — | — | $-1.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial111 Valuation Multiples
111 trades at 0.0x EV/Revenue multiple, and 1.5x EV/EBITDA.
111 Financial Valuation Multiples
As of May 10, 2026, 111 has market cap of $53M and EV of $6M.
111 has a P/E ratio of (5.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 111 Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


111 Margins & Growth Rates
In the most recent fiscal year, 111 reported gross margin of 6%, EBITDA margin of 0%, and net margin of (1%).
111 Margins
111 Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
111 Operational KPIs
111's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
111 Competitors
111 competitors include SOFTMAX, Mister Spex, Beforepay, Deepnoid, BIT Computer, PharmX Technologies, Autopedia, Niyogin Fintech, MeVis and LendInvest.
Most 111 public comparables operate across Telemedicine & Virtual Care, Online Lending, Healthcare Software, B2B E-commerce, Vertical E-commerce, HealthTech, FinTech, B2B SaaS and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 1.1x | 9.1x | — | |||
| 0.2x | 0.2x | (1.5x) | (6.8x) | |||
| 2.4x | 2.1x | 8.6x | 7.7x | |||
| 8.3x | — | (6.5x) | — | |||
| 1.4x | — | 4.9x | — | |||
| 10.0x | — | 52.8x | — | |||
| 0.6x | — | 5.5x | — | |||
| 2.5x | — | (62.5x) | — | |||
This data is available for Pro users. Sign up to see all 111 competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 111
| When was 111 founded? | 111 was founded in 2013. |
| Where is 111 headquartered? | 111 is headquartered in China. |
| How many employees does 111 have? | As of today, 111 has over 1K employees. |
| Is 111 publicly listed? | Yes, 111 is a public company listed on Nasdaq. |
| What is the stock symbol of 111? | 111 trades under YI ticker. |
| When did 111 go public? | 111 went public in 2018. |
| Who are competitors of 111? | 111 main competitors include SOFTMAX, Mister Spex, Beforepay, Deepnoid, BIT Computer, PharmX Technologies, Autopedia, Niyogin Fintech, MeVis, LendInvest. |
| What is the current market cap of 111? | 111's current market cap is $53M. |
| What is the current revenue of 111? | 111's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of 111? | Current revenue multiple of 111 is 0.0x. |
| Is 111 profitable? | No, 111 is not profitable. |
| How many companies 111 has acquired to date? | 111 hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies 111 has invested to date? | 111 hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 111
Lists including 111
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.